ARGENX SE
Business
Argenx is a biopharmaceutical company developing and commercializing monoclonal antibody and protein therapeutic products for autoimmune and other rare diseases. The company's marketed product is VYVGART (efgartigimod), approved for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia in Japan, with pipeline candidates including empasiprubart and adimanebart for additional indications. Argenx operates a global commercialization infrastructure with distribution partnerships and direct sales operations across the U.S., EU, and other jurisdictions.
Summary from 20-F filed 2026-03-19
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $1.29B |
| Total assets | $8.68B |
| Total liabilities | $1.36B |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ARGENX SE's CIK number?
ARGENX SE's SEC CIK number is 0001697862 (1697862). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ARGENX SE's SEC filings?
All of ARGENX SE's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.